Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 241

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 19
Chunk 241
---
356 424,527

During the year ended March 31, 2024, Cencora Group, McKesson Group and Cardinal Health Group, represented more than 10% of Takeda’s sales. The sales to Cencora Group, McKesson Group and Cardinal Health Group were JPY 579,065 578,767 436,951

During the year ended March 31, 2025, McKesson Group and Cencora Group represented more than 10% of Takeda’s sales. The sales to McKesson Group and Cencora Group were JPY 592,323 577,017

F-26

Other Revenue Information

Contract Balances

                                                 JPY (millions)                                      
                                                 As of March 31                                      
                                                 2024                             2025               
 ─────────────────────────────────────────────────────────────────────────────────────────────────────
  Receivables from contracts with customers                                                          
  Trade receivables (Note 17)                    ¥                   612,439      ¥         651,414  
  Contract assets                                                                                    
  Unbilled receivables                                                 2,574                  1,372  
  Contract liabilities                                                                               
  Deferred income (Note 24)                                            8,259                 23,547  
  Advance payments                               45                               64                 

Takeda’s contract assets relate to the right to receive consideration where performance was completed based on the contract, and trade receivables are recognized when the right to receive consideration becomes unconditional.

Takeda’s contract liabilities primarily relate to out-licensing arrangements or product purchase and supply agreements where Takeda receives cash consideration prior to the completion of its performance obligations under the agreements. The revenue recognized during the years ended March 31, 2023, 2024, and 2025 that was included in the contract liability balance as of the beginning of the year was JPY 49,319 5,526 5,634 79,251 80,794 97,560

Transaction price allocated to the remaining performance obligations

                                                 JPY (millions)                                                                                                                                       
                                                                     Total                  Duration of the remaining performance obligations                                                         
                                                                                            Within one year                                                    Between one and five years             
  Contract liabilities as of March 31, 2024                          ¥           8,304      ¥                                                       6,119      ¥                               1,668  
  Contract liabilities as of March 31, 2025                                     23,